Editorial Manager(tm) for Gastroenterology Manuscript Draft

Manuscript Number:

Title: A rare cause of bloody stools in a 57-year-old woman patient with hepatocellular carcinoma

Article Type: Clinical Challenges and Images in GI

Section/Category: Human Research - Whole Body

Corresponding Author: Dr. Jen-Wei Chou, M.D.

Corresponding Author's Institution: China Medical University Hospital

First Author: Shang-Fen Huang

Order of Authors: Shang-Fen Huang; Jen-Wei Chou, M.D.; Hsueh-Chou Lai, M.D.

Jan. 07, 2010

Dear editors,

We submitted our manuscript entitled "A rare cause of bloody stools in a 57-year-old woman patient with hepatocellular carcinoma" to clinical challenges and images in GI of "Gastroenterology". It has not been submitted for publication nor has it been published in whole or in part elsewhere. All authors listed on the title page meet criteria for authorship. I attest to the fact that all authors listed on the title page have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to your journal. We believe the paper may be of particular interest to the readers of your journal.

To the best of our knowledge and belief, there is no document correlated with possible conflicts of interest, sources of financial support, corporate involvement, and patent holdings for each author needing attaching. Correspondence and phone calls about the paper should be directed to Jen-Wei Chou at the following address, phone and fax number, and

e-mail address :

Dr. Jen-Wei Chou , Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, No. 2, Yuh-Der Road, North District, Taichung 40447, Taiwan, R.O.C.

E-mail: codecol@yahoo.com.tw

Telephone: + 886-4-22052121 ext. 2220, Fax: +886-4-22023119

Thanks very much for your attention to our paper .

Sincerely yours, Dr. Jen-Wei Chou

A rare cause of bloody stools in a 57-year-old woman patient with hepatocellular carcinoma

Shang-Fen Huang, Jen-Wei Chou, M.D., Hsueh-Chou Lai, M.D.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, China

Medical University Hospital, Taichung, Taiwan

Conception and design: Dr. Shang-Fen Huang

Analysis and interpretation of the data: Dr. Hsueh-Chou Lai

Critical revision of the article for important intellectual content: Dr. Jen-Wei Chou

Correspondence and reprint requests to: Dr. Jen-Wei Chou

Division of Gastroenterology and Hepatology, Department of Internal Medicine, China

Medical University Hospital, No. 2, Yuh-Der Road, North District, Taichung 40447, Taiwan

E-mail: codecol@yahoo.com.tw

Telephone: + 886-4-22052121 Ext. 2220, Fax: +886-4-22023119

No conflicts of interest exists

Keywords: endoloop, hepatocellular carcinoma, rectal metastasis

Question

A 57-year-old woman was admitted to our hospital because of a 1-day history of bloody stools. She had several decades' medical history of hepatitis C virus infection and type 2 diabetes mellitus. One and half years ago before this admission, a hepatic mass in the right lobe was found by abdominal ultrasound. She then underwent a right segmentectomy for the liver tumor. The histological examination of the resected tumor revealed a hepatocellular carcinoma (HCC). Three months prior to this admission, she suffered acute onset of right limb weakness. Brain computed tomography scan demonstrated a mass lesion in the left frontal lobe. She underwent a craniotomy for removal of the brain tumor. The histological study of the resected brain tumor revealed a metastatic HCC. This time, bloody stools developed one day before this admission. Chest X-ray demonstrated a 5 cm-size mass in the left lower lung, suggestive of metastasis (Figure A). Colonoscopy demonstrated a 1.0 cm-sized ulcer in the rectum (Figure B). Moreover, a giant soft tissue-like lesion with adherent blood clots was identified in the rectum, suggesting the bleeding point (Figure C). The soft tissue-like lesion could not be removed by water flushing. We decided to remove it by endoscopic polypectomy. In order to prevent the postoperative bleeding, we first applied an endoloop (MAJ-254, Olympus, Tokyo, Japan) to ligate the base of this rectal lesion. However, the rectal lesion was dissected into two parts after ligation. The resected part of rectal lesion was sent for a histological study. What is the diagnosis of this rectal lesion?

Answer

On histological examination, the resected rectal lesion demonstrated small amount freely floating nests of atypical epithelial tumor cells with moderate nuclear anaplasia and granular eosinophilic cytoplasm in the mucoid exudates and blood clots (Figure D, arrows, hematoxylin and eosin; original magnification, \times 400). The immunohistochemical stain of the tumors cells showed positivity for Hep Par-1 (Figure E, arrows; original magnification, \times 400). Therefore, a diagnosis of metastatic HCC was made. Due to HCC with multiple metastases, the patient received palliative treatment. HCC is a very common cancer worldwide with a frequent intrahepatic and extrahepatic metastasis. Extrahepatic metastasis of HCC usually occurs in the lungs, lymph nodes, musculoskeletal system, adrenal glands, and peritoneum.^{1,2} In contrast, the gastrointestinal (GI) tract is a rare metastatic site of HCC, especially in the colon and rectum.¹ Poor performance status, portal vein thrombosis, untreated patient, and Child-Pugh score C were the predictors of extrahepatic metastasis of HCC at the initial diagnosis of HCC.³ The clinical manifestations of GI metastasis of HCC include abdominal pain, hemorrhage, intussusception, and intestinal obstruction. Endoscopic examination is the major diagnostic modality for GI metastasis of HCC, including esophagogastroduodenoscopy, colonoscopy, and enteroscopy. In the treatment of HCC patients with extrahepatic metastasis, most patients mainly undergo treatment for the primary HCC.³ Treatment of extrahepatic metastases is only indicated in HCC patients who have

good hepatic reserve, intrahepatic tumor stage (T0-T2), and are free of portal venous invasion.³

References

- Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703.
- 2. Natsuizaka M, Omura T, Akaike T, Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005;20:1781-1787.
- 3. Uka K, Aikata H, Takaki S, et al, Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007;13:414-420.

Figure Legends

Figure A. Chest X-ray revealed a 5 cm-sized mass in the left lower lung, suggestive of metastasis.

Figure B. Colonoscopy demonstrated a 1.0 cm-sized ulcer in the rectum.

Figure C. Colonoscopy also demonstrated a giant soft tissue-like lesion with adherent blood clots in the rectum, suggesting the bleeding point.

Figure D. On histological examination, the resected rectal lesion demonstrated small amount freely floating nests of atypical epithelial tumor cells with moderate nuclear anaplasia and granular eosinophilic cytoplasm in the mucoid exudates and blood clots (Figure *D*, arrows, hematoxylin and eosin; original magnification, \times 400).

Figure E. The immunohistochemical stain of the tumors cells showed positivity for Hep Par-1, indicative of metastatic hepatocellular carcinoma (arrows, original magnification, \times 400).

Figure A Click here to download high resolution image











American Gastroenterological Association (AGA) Institute Gastroenterology Editorial Office 4930 Del Avenue Bethesda, MD. 20814

Please fax this signed agreement to Chris Lowe at 301-654-1140

RE: Manuscript title: (Enter your manuscript title here)

A rare cause of bloody stools in a 57-year-old woman patient with

hepatocellular carcinoma

I agree to pay for the cost of color reproduction for the figures that were reviewed with the manuscript above. I understand the estimated cost is \$650 for the first color figure and \$100 for each additional color figure.

Signature: Date: Jen-Wei Chou

Jan 07. 20%

Print Name:

Copyright Assignment, Authorship Responsibility, NIH Funding, Financial Disclosure, Institutional Review Board/Animal Care Committee Approval, and Sponsorship

Copyright Assignment. In consideration of the American Gastroenterological Association (AGA) Institute (the "AGA Institute") taking action to review and credit the below-identified submission (the "Manuscript"), and for other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned authors und/or creators (the "Authors"), jointly and severally, hereby transfer, convey, and assign to the AGA Institute, free and clear of any lices, licenses or encumbrances, the entire right, title, and interest in and to the Manuscript throughout the world, including without limitation in and to any and all copyrights for the Manuscript fincluding but not limited to rights to copy, publish, except, collect royalties and make derivative works) in print, electronic, Internet, broadcast, and all other forms and media now or hereafter known, and for any and all causes of action heretofore accused in Authors' favor for infringement of the aforesaid copyrights, to have and to hold the same unto the AGA Institute, its successors and assigns, for and during the existence of the aforesaid copyrights, and all renewals and extensions thereof. At any time and from time to time horoafter, the Authors shall upon the AGA Institute's written request take any and all steps and execute, acknowledge and deliver to the AGA Institute any and all further instruments and assurances necessary or expedient in order to vest the aforesaid copyrights and causes of action more effectively in the AGA Institute. The Authors retain the nonexclusive permission to use all or part of the Manuscript in future works of their own in a noncompeting way, provided proper copyright credit is given to the AGA Institute. Should the AGA Institute finally determine that it will not publish the Manuscript, the AGA Institute agrees to assign its rights therein back to the Authors.

Authorship Responsibility. I, the undersigned Author, certify that I have participated sufficiently in the intellectual content, the analysis of data, if applicable, and the writing of the Manuscript, to take public responsibility for it. I have reviewed the final version of the Manuscript, believe it represents valid work, and approve it for publication. As an Author of this Manuscript, I certify that, except to the extent expressly credited to others in the text of the Manuscript: the entire Manuscript is an original creation of the Authors; and none of the material in the Manuscript has been published previously, is included in another manuscript, or is currently under consideration for publication elsewhere. I also certify that this Manuscript has not been accepted for publication elsewhere, and that I have not assigned, licensed, or otherwise transferred any right or internat in the Manuscript to anyone. Moreover, should the AGA Institute or the editors of GASTROENTEROLOGY request the data upon which the Manuacript is based, I shall produce it. Authors are responsible for applying for permission for both print and electronic rights for all borrowest materials and are responsible for paying any fees related to the applications of these permissions.

Institutional Review Board/Animal Care Committee Approval. I, the undersigned Author, certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research. Sponsorship. I, the undersigned author, certify that I had full access to all of the data in this study, and I take responsibility for the

integrity of the data and the accuracy of the data analysis. ma 19 year-old worken patient with shalls af. party A LOK CALLE Manuscript true:

Signatures: Each Author must sign and date this statement and assignment. In the case of a work made for hire, the employer(s) must also sign For example, for any Manuscript including any portion created in the course of employment for another (whether as a regular employee of an independent contractor) requires the signature of the relevant employer(s). nepotaglalan

				- 23
Prine Name: Shang - 7	ten Harmang to	7 Brid Name (Such	- Chon Dar Jan ??	10 10
Print Name Ten-We	i Chart - Ja	C J Print Name	Date:	.0.7
Print Name: Employer signature(s) as Author (res	Date: quited for works made for hite)	Print Name:	Date:	
(Employer)		(Employer) By:		
Balai Mamat	Date:	Print Name:	Date:	

TAILINERG

If this Manuscript exists in the public dumain because it was written as part of the official duties of the Authon as employees of the U.S. government, check this box.

National Institutes of Health (NIH) Funding. My manuscript was supported in part, or in whole, by the NIH. In accordance with the NIH Public Access Policy, I understand that my manuscript, should it be accepted for publication, will be submitted to PubMed Central (PMC). I understand that my manuscript will therefore he freely accessible by the public via PMC receive months from the date of its publication. My NIH grant number is

Financial Disclosure. Check the appropriate box and sign where indicated. All Authors must sign one of the statements below. I I the undersigned Author, certify that I have no financial arrangements (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements, research support, major honoraria, etc.) with a company whose product figures prominently in the submitted manuscript or with a company making a competing product except as disclosed on a separate attachment. All funding sources supporting the work are acknowledged on the title page.

Date:

Print Name: .

1, the undersigned Author, certify that I have included on the title page of the manuscript any financial arrangements (e.g., consultancies, stock ownership, equiry interests, patent-licensing arrangements, research support, major humonaria, etc.) that I have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. All funding sources supporting the work are acknowledged on the title page.